Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2018

Open Access 01-02-2018 | Epidemiology

Real-world treatment in patients with HER2+ metastatic breast cancer

Treatment decisions in HER2+ mBC

Authors: R. Colomer, P. Hall, M. Szkultecka-Debek, R. C. Bondi, A. Flinois, S. Auziere, J. Y. Le Cléac’h

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Abstract

Purpose

The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in the real-world setting. Secondary objectives were to describe the factors that influence the decision to prescribe a first and second-line antitumour treatment.

Methods

Retrospective chart review of 3068 cases in Spain, Italy, the Netherlands and the UK.

Results

First and second-line treatments and regimens are consistent with the clinical guidelines, especially for recently initiated treatments. Age and performance status (PS) of patients impact treatment patterns: younger patients received more innovative treatments than elderly patients. In addition, while most patients received a first antitumor treatment, the rate of patients who continue to subsequent lines of therapy is low (55% transitioning from 1st to 2nd line; 58% from 2nd to 3rd line). Age and PS are key factors in the decision to prescribe further antitumor treatment.

Conclusion

Fewer HER2+ mBC patients than expected receive a second and third line therapy. Guidelines should make specific recommendations for older patients or those with a poor PS.
Footnotes
1
A decision tree is a classifier with a tree structure. It is the result of a multivariate analysis which consists of determining a sequence of nodes. A decision node specifies a significant test on an independent variable (predictor). A leaf node indicates the threshold for significance of the variable, and divides the sample into two sub-samples. Decision trees classify instances by starting at the root of the tree and moving through it until a leaf node.
 
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRefPubMed
2.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed
3.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 200(3):290–297CrossRefPubMed
4.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E (2017) 3rd ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 3). Ann Oncol 28(1):16–33PubMed
5.
Tripathy et al (2014) The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer 14:307CrossRefPubMedPubMedCentral
6.
7.
Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R et al (2014) Hurdles and delays in access to anti-cancer drugs in Europe. Ecancermedicalscience 8:482CrossRefPubMedPubMedCentral
8.
Kaufman P, Brufsky A, Mayer M, Rugo H, Tripathy D, Yood M, Feng S, Wang L, Quah C, Yardley D (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135:875–883CrossRefPubMedPubMedCentral
9.
Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S (2015) Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer 15:892CrossRefPubMedPubMedCentral
10.
Maida V, Peck J, Ennis M, Brar N, Maida AR (2010) Preferences for active and aggressive intervention among patients with advanced cancer. BMC Cancer 10:592CrossRefPubMedPubMedCentral
11.
Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG (2014) Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ 348:g1219CrossRefPubMedPubMedCentral
12.
13.
Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I et al (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160CrossRefPubMed
14.
Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C et al (2007) Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8(12):1101–1115CrossRefPubMed
15.
Strulov Shachar S, Hurria A, Muss HB (2016) Targeted Therapies in Older Adults With Breast Cancer: What Do We Know? J Clin Oncol 34(28):3486–3488CrossRefPubMed
16.
Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A et al (2013) Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 142(1):89–99CrossRefPubMedPubMedCentral
17.
Le Saux O, Falandry C, Gan HK, You B, Freyer G, Peron J (2016) Inclusion of elderly patients in oncology clinical trials. Ann Oncol 27(9):1799–1804CrossRefPubMed
18.
Barrios CH, Anton A, Delaloge S, Montemurro F, Wuerstlein R, Robb S, et al (2015) Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study. Proceedings of ASCO; J Clin Oncol 33((suppl; abstr 603)). Available from: http://​meetinglibrary.​asco.​org/​content/​148100-156
19.
Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L et al (2015) Improving the evidence base for treating older adults with cancer: american society of clinical oncology statement. J Clin Oncol 33(32):3826–3833CrossRefPubMed
Metadata
Title
Real-world treatment in patients with HER2+ metastatic breast cancer
Treatment decisions in HER2+ mBC
Authors
R. Colomer
P. Hall
M. Szkultecka-Debek
R. C. Bondi
A. Flinois
S. Auziere
J. Y. Le Cléac’h
Publication date
01-02-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4567-z

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue

Epidemiology

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

Clinical trial

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Clinical trial

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer

Preclinical study

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer

Brief Report

Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot

Clinical trial

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits